Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (GONO)

被引：0
|
作者：
Falcone, A.
Brunetti, I. M.
Benedetti, G.
Evangelista, W.
Picone, V.
Vitello, S.
Rosso, R.
Granetto, C.
Porcile, G.
Masi, G.
机构：
[1] Univ Study Pisa, Osped Civile, UO Oncol Med, Livorno, Italy
[2] Osped S Chiara, UO Oncol Med, Pisa, Italy
[3] Osped Bellaria, UO Oncol Med, Bologna, Italy
[4] Osped S Giovanni Molinette, COES, Turin, Italy
[5] Policlin Umberto 1, UO Oncol Med, Rome, Italy
[6] Osped S Elia, UO Oncol Med, Caltanissetta, Italy
[7] IST, Genoa, Italy
[8] Osped S Croce & Carle, SC Oncol Med, Cuneo, Italy
[9] Osped S Lazzaro, UO Oncol, Alba, Italy
[10] Osped Civile, UO Oncol Med, Livorno, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：167 / 168
页数：2
相关论文
共 50 条
  • [1] Biweekly irinotecan, oxaliplatin and infusional 5FU/LV (FOLFOXIRI) versus folfiri as first-line treatment of metastatic colorectal cancer (MCRC):: Results of a randomized phase III trial by the gruppo oncologico nord ovest (GONO)
    Masi, G.
    Allegrini, G.
    Brunetti, I.
    Murr, R.
    Ricci, S.
    Benedetti, G.
    Crino, L.
    Fanchini, L.
    Bertetto, O.
    Picone, V.
    Cortesi, E.
    Vitello, S.
    Chiara, S.
    Rosso, R.
    Granetto, C.
    Merlano, M.
    Porcile, G.
    Alabisio, O.
    Fioretto, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2005, 16 : 7 - 7
  • [2] The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (GONO).
    Falcone, A.
    Masi, G.
    Brunetti, I.
    Benedetti, G.
    Bertetto, O.
    Picone, V.
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Ricci, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 149S - 149S
  • [3] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
    Falcone, Alfredo
    Ricci, Sergio
    Brunetti, Isa
    Pfanner, Elisabetta
    Allegrini, Giacomo
    Barbara, Cecilia
    Crino, Lucio
    Benedetti, Giovanni
    Evangelista, Walter
    Fanchini, Laura
    Cortesi, Enrico
    Picone, Vincenzo
    Vitello, Stefano
    Chiara, Silvana
    Granetto, Cristina
    Porcile, Gianfranco
    Fioretto, Luisa
    Orlandini, Cinzia
    Andreuccetti, Michele
    Masi, Gianluca
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1670 - 1676
  • [4] FOLFOXIRI improves survival compared to FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC):: Updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (GONO)
    Masi, G.
    Barbara, C.
    Brunetti, I
    Pfanner, E.
    Murr, R.
    Ricci, S.
    Benedetti, G.
    Crino, L.
    Evangelista, W.
    Bertetto, O.
    Picone, V
    Cortesi, E.
    Vitello, S.
    Chiara, S.
    Granetto, C.
    Merlano, M.
    Fioretto, L.
    Orlandini, C.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI3 - XI4
  • [5] FOLFOXIRI VERSUS FOLFIRI AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS: PRELIMINARY SAFETY RESULTS OF A RANDOMIZED PHASE III TRIAL OF THE GRUPPO ONCOLOGICO NORD OVEST (GONO)
    Falcone, A.
    Masi, G.
    Allegrini, G.
    Brunetti, I.
    Pfanner, E.
    Bertetto, O.
    Evangelista, W.
    Crino, L.
    Benedetti, G.
    Cortesi, E.
    Picone, V.
    Rosso, R.
    Chiara, S.
    Vitello, S.
    Merlano, M.
    Granetto, C.
    Fioretto, L.
    Ribecco, A.
    Alabiso, O.
    Ostellino, O.
    Porcile, G.
    Pucci, F.
    Bagnulo, A.
    Di Lieto, M.
    Filidei, M.
    Cupini, S.
    Marcucci, L.
    Barbara, C.
    Andreuccetti, M.
    Ricci, S.
    ANNALS OF ONCOLOGY, 2004, 15 : 58 - 58
  • [6] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) IN METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS OF A PHASE II GONO TRIAL
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Di Marsico, Roberta
    Antonuzzo, Andrea
    Baldi, Giacomo Giulio
    Stasi, Irene
    Pfanner, Elisabetta
    Ciarlo, Andrea
    Del Monte, Francesca
    Conte, Davide
    Iacovelli, Roberto
    Sonaglio, Claudia
    Granetto, Cristina
    Donati, Sara
    Andreuccetti, Michele
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2009, 20
  • [7] Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II GONO trial
    Masi, G.
    Salvatore, L.
    Fornaro, L.
    Vasile, E.
    Baldi, G. G.
    Stasi, I.
    Ciarlo, A.
    Tuzi, A.
    Andreuccetti, M.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
  • [8] Biweekly 5FU/LV+CPT-11 (FOLFIRI) vs 5FU/LV+CPT-11+LOHP (FOLFOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results from a randomized phase III study by the Gruppo Oncologico Nord Ovest (GONO
    Falcone, Alfredo
    Ricci, Sergio
    Brunetti, Isa Maura
    Evangelista, Walter
    Benedetti, Giovanni
    Cortesi, Enrico
    Chiara, Silvana
    Merlano, Marco
    Miraglia, Stefania
    Masi, Gianluca
    ANNALS OF ONCOLOGY, 2004, 15 : 84 - 84
  • [9] Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by Gruppo Oncologico NORD-OVEST (GONO)
    Bursi, S.
    Masi, G.
    Antonuzzo, A.
    Cerri, E.
    Loupakis, F.
    Barbara, C.
    Barletta, M.
    Allegrini, G.
    Cupini, S.
    Ricci, S.
    Brunetti, I
    Pfanner, E.
    Lencioni, M.
    Murr, R.
    Petrini, I
    Tognarini, L.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI41 - XI41
  • [10] Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (IR)+5-FU/LV (IRFL) followed by docetaxel (T)+5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico NORD-OVEST (GONO)
    Loupakis, F.
    Masi, G.
    Fontana, E.
    Allegrini, G.
    Bursi, S.
    Barbara, C.
    Cerri, E.
    Barletta, M. T.
    Picone, V
    Mentuccia, L.
    Granetto, C.
    Fea, E.
    Pfanner, E.
    Murr, R.
    Brunetti, I
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI50 - XI50
12345